Create your page here
Urban pigeon friends – Scaremongering tactics and shooting not a solution
Edit The Malta Independent 31 Jul 2016
We have recently had a “Hate pigeon week”. . Some weeks ago, pigeons were cruelly massacred with air rifles at the instigation of the Balzan Local Council ... The facts are these. Feral urban pigeons do not pose a risk to people’s health ... 15 July) ... ... Candida yeasts are found everywhere ... The second is ‘bird fancier’s lung’ (allergic pulmonary alveolitis, hypersensitivity pneumonitis)....
Bee-keeping industry buzzing for Montreal-based company
Edit Toronto Sun 25 Apr 2016
According to Alveole's website, there are 15 beehive locations in Toronto, a couple in Quebec City and Maine, and more than 250 locations in Montreal, where the company started in 2012. Alveole says its hands are full with their existing locations, so they won't be expanding to any more cities for the time being ... She got a hive from Alveole last summer and saw a prolific 30-kilogram honey payoff by fall....
Round-The-World Trip Is On Track For Solar Airplane (SEIA - Solar Energy Industries Association)
Edit Public Technologies 21 Apr 2016
(Source. SEIA - Solar Energy Industries Association). Last July, pilot André Borschberg wearily stepped out the cockpit he'd been confined to for five days and five nights ... Its frame is primarily constructed of ultralight materials like carbon fiber and alveolate foam, but most essential to its successful round-the-world trip are the 17,248 solar cells atop its wings, fuselage and stabilizers ... Let's use them also on the ground!' ... (noodl....
The problems with pigeons...
Edit DNA India 20 Mar 2016
-->. There is an alarming rise in the number of pigeons in the city ... And so, feeding pigeons at kabutar khana and similar feeding centres has become a common sight ... Dr Kedar Toraskar, Consultant, Critical Care & Pulmonologist, Wockhardt Hospitals, Mumbai Central shares, "Frequenting kabutar khanas may lead to a disease called extrinsic allergic alveolitis, also known as pigeon breeders disease or bird fancier's disease ... ....
Boehringer Ingelheim's Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer -Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib is superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib[1]-More patients on afatinib were free of cancer growth 18 and 24 months after the start of treatment (27% vs 15% and 18% vs 8%, respectively)[1]-The overall frequency of patients experiencing serious adverse events and discontinuing treatment due to adverse events was similar in both arms[1]
Edit PR Newswire 27 Jan 2016
RIDGEFIELD, Conn., Jan. 27, 2016 /PRNewswire/ -- Boehringer Ingelheim announced today the results of the LUX-Lung 7 trial ... 44.4% vs gefitinib ... Results ... Interstitial Lung Disease (ILD) ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal ... here ... ....
FDA and EMA accept regulatory applications for Boehringer Ingelheim's Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung - Regulatory submissions are based on positive data from LUX-Lung 8 study that showed a significant delay in progression of lung cancer (progression-free survival, primary endpoint) and a significant improvement in overall survival for Gilotrif compared to Tarceva (erlotinib)(1)- LUX-Lung 8 is a large, prospective Phase III head-to-head trial that compared two EGFR-directed treatments in patients with squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy- Afatinib has also been granted orphan drug designation by the FDA - a status given to a product intended for the treatment of a rare disease or condition
Edit PR Newswire 25 Aug 2015
RIDGEFIELD, Conn., Aug. 25, 2015 /PRNewswire/ -- Boehringer Ingelheim today announced that both the U.S ... Dr ... 44%) and pain (40% vs ... 10% vs ... 4% vs ... 10% vs. 6%) ... Interstitial Lung Disease (ILD) ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal ... ....
Cryptic infection of a broad taxonomic and geographic diversity of tadpoles by Perkinsea protists
Edit PNAS 05 Aug 2015
Abstract. The decline of amphibian populations, particularly frogs, is often cited as an example in support of the claim that Earth is undergoing its sixth mass extinction event ... a parasitic group within the alveolates exemplified by Perkinsus sp., a “marine” protist responsible for mass-mortality events in commercial shellfish populations ... ....
Tenderness (Original Mix)
Edit MUZU.TV 05 Jun 2015
Watch the official Tenderness (Original Mix) video by Alveol, Ignatyuk in HD on WWW.MUZU.TV and check out the latest new music releases and playlists for free. ....
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung - In the Phase III LUX-Lung 8 trial, afatinib significantly improved overall survival compared to erlotinib, reducing the risk of death by 19% in patients with advanced squamous cell carcinoma of the lung, previously treated with first-line chemotherapy- Afatinib significantly delayed progression of lung cancer (primary endpoint) and improved control of cancer-related cough and shortness of breath compared to erlotinib- The overall rate of severe adverse events (>/= grade 3) was similar between both therapies, with differences observed in the incidence of certain side effects- Global regulatory submissions are planned later this year to treat this patient population
Edit PR Newswire 31 May 2015
Significantly more patients treated with afatinib were still alive at one year compared to those treated with erlotinib (36.4 vs. 28.2%) ... 57.5%) ... 9.9/0.5 vs ... 4.1 vs ... Interstitial Lung Disease (ILD) ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal....
- 1
- 2
- 3
- 4
- 5
- Next page »
